It really is a catch 22 here. The lag between the progress updates, lengthiness of the entire process to incorporate an innovation into an existing product before commercialising is what keeps us at the current SP level. The fundamentals of this company far outweighs the current SP. The uncertainties behind the length of the process is what keeps us at bay. No matter how good a single piece of announcement is those who buy in straight after an announcement released in fear of missing the run will be burnt. There is no point in buying up after an announcement on anticipation of sustained gains if it simply states that the company is making excellent progress. It is better off to wait a few weeks and let the traders exit before us long termers can once again load up on OBJ. IMO the question that if answered, will cause a sustained re-rating is where abouts in the timeline are we? How long until its all wrapped up? Minutes are measure in hours and days in weeks when you talk about the biotech sector and i have most certainly acknowledged that. Could probably give the Dalai Lama a run for his money if patience was the name of the game ;)
Outrageous to think that a small cap company with a MC under 25million could be working with one of the largest pharmas in the world; GSK, in an exclusive agreement to develop a a range of FMCG dental product which is a branch of their consumer healthcare division to drive GSK's future success along with an unknown multinational pharma utilising our technology to deliver an existing therapeutic drug that already has multi-billion dollar revenue streams and are currently in the marketing phase due to be commercialised very soon could still be at the current SP.
We could very well be in for a cracker of an announcement with the FMCG-1 announcement. My guess is that a therapeutic agent utilising our powerless ETP technology will be for weaker symptoms and the big money will lie in their powered DP application. The DP technology can be used for professional and retail applications for precise deliveries of consumables or targeted delivery of active drugs. These are reuseable and can be applied for an extended period of time... Applications in hospitals? Clinics? Not too sure but i believe thats where the big money lies.
ETP-panadol-esc patch for everyday consumption DP-migranes/chronic pains perscribed via a doctor? FMCG does throw this assumption off though... Any thoughts?
OBJ Price at posting:
2.1¢ Sentiment: Hold Disclosure: Held
(20min delay)